Nervous system injury neuropathy

Peripheral nerve injury triggers a local immune reaction in the nerve’s own lining, and new research shows that disrupting that reaction can prevent the resulting chronic pain entirely in mice.

The question asks about nervous system injury causing neuropathy, a broad topic. The retrieved evidence mostly covers neuropathic pain, not the full spectrum of neuropathy (sensory loss, weakness, autonomic problems), and what reaches human trials is mostly small and short-term. One 2026 study stands out for showing a specific causal mechanism in mice: after a nerve is cut, the dorsal root ganglion (the nerve cell body cluster just outside the spine) develops organized clusters of B cells in its covering tissue — what the authors call tertiary lymphoid structures [1]. Delete those B cells with a single injection of a CD20 antibody at the time of injury, and the mice never develop the mechanical hypersensitivity that normally follows [1]. The same effect occurred when they genetically removed a protein needed for germinal center B cells to form [1]. This is not a pain reliever; it is a prevention strategy targeting the immune reaction itself.

For human neuropathic pain already present, the options are less dramatic. A systematic review found that about 53 in 100 people with spinal cord injury report neuropathic pain, and available treatments provide modest relief at best [2]. Intravenous lidocaine produced a 50% pain reduction in about 1 in 3 people (number needed to treat of 3) in a small 24-patient crossover trial, though side effects were common [5]. A capsaicin 8% patch reduced pain by 30% or more in roughly 4 in 10 people at 15 days, but only about 2 in 10 could cut back on their other pain meds [7]. A dronabinol (synthetic THC) pilot trial found no significant difference from an antihistamine control — neither worked well [4]. Virtual walking therapy showed variable results in just four people [3]. Surgery and stimulation help some: spinal cord stimulation for nerve-injury pain showed about 6 in 10 patients had a positive trial, and of those implanted, about 56 in 100 had a favorable long-term outcome [6].

The key limitation in this evidence: none of the human trials test prevention, and only the 2026 mouse study [1] shows an intervention that actually blocks neuropathy from developing. The human pain treatments are managing a symptom, not reversing or preventing nerve injury. The B-cell mechanism has not been tested in people yet.

My call: the evidence for preventing neuropathy after nerve injury by targeting the immune response is promising but only in animals; for treating established neuropathic pain, the available human options produce modest and inconsistent relief. Confidence in the animal mechanism: moderate. Confidence in human treatments: low — the trials are too small, too short, and too many used no true placebo.